B of A Securities Downgrades Edwards Lifesciences to Neutral, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has downgraded Edwards Lifesciences (NYSE:EW) from Buy to Neutral and lowered the price target from $105 to $75.

July 25, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B of A Securities has downgraded Edwards Lifesciences from Buy to Neutral and lowered the price target from $105 to $75.
The downgrade from Buy to Neutral and the significant reduction in the price target from $105 to $75 by B of A Securities is likely to negatively impact investor sentiment and the stock price of Edwards Lifesciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100